CordenPharma Unveils Over €500 Million Investment in New Peptide Facility in Switzerland CordenPharma is investing over €500 million to establish a state-of-the-art peptide facility in Basel, Switzerland, enhancing its production capabilities.

CordenPharma Unveils Over €500 Million Investment in New Peptide Facility in Switzerland #Switzerland #Basel #CordenPharma #Peptide_Manufacturing #Basel_Switzerland